BOSTON--(BUSINESS WIRE)--VoxNeuro Inc. (“VoxNeuro” or “the Company”), a company that develops leading-edge EEG-based brain performance software, announced the completion of its second financing round with nearly USD $3.4 million raised. The funding round was led by the Company’s largest shareholder, in addition to its strategic investor g.tec, a brain-computer interface and neurotechnology company that serves as VoxNeuro's strategic supplier of EEG hardware. The financing will be used to execute commercial expansion plans to scale clinical installations across the US to meet the growing demand for cognitive assessments, promote brain health equity, and continue to perform software enhancements through research and development.
“The continuous support of our investors has contributed to VoxNeuro’s tremendous progress in our endeavor to become The Brain Company and empowers us to scale our product across more clinics. Our unwavering commitment to giving everyone’s brain a voice through research-intensive, innovative solutions adds meaningful value to healthcare providers and aims to improve patient outcomes,” says Jason Flowerday, Chief Executive Officer at VoxNeuro.
The closing follows a quarter of significant milestones which include: securing ten new client agreements; partnering with Boston University to develop validated diagnostic tools for targeted application in Concussion and Alzheimer’s patients; exhibiting at the 75th American Academy of Neurology (AAN) Annual Meeting in Boston and the Collision tech conference in Toronto. Additionally, VoxNeuro delivered a keynote presentation on the value of adding objective data for all players via their language-agnostic medical technology at the Annual Professional Hockey Athletic Trainers Society and Society Of Professional Hockey Equipment Managers (PHATS/SPHEM) Conference in Phoenix, AZ with a target audience of medical teams and trainers from the National Hockey League (NHL), American Hockey League (AHL) and Canadian Hockey League (CHL).
“This financing marks a pivotal moment for VoxNeuro and is a testament to the dedication of our network of investors and collaborators,” says Edward Jonasson, Chief Financial Officer at VoxNeuro. “Their support helps accelerate our product development and operational model, granting us the opportunity to enhance our market presence and increase shareholder value while providing a path to revenue growth and penetration into the US market.”
Further in its robust pipeline, VoxNeuro is developing a machine-learning (ML) enhancement to its current clinical tool. The new machine learning algorithm boasts advanced features that promote increased precision, specificity and a more holistic view of patients’ cognitive health. With an established client success team along with an extensive sales and marketing strategy in place, the Company continues to transform the brain health landscape with its objective cognitive health assessments.
About VoxNeuro - Giving Everyone’s Brain a Voice
VoxNeuro develops leading-edge EEG-based brain performance software to objectively assess cognitive function. Backed by 40 years of research, its first in-clinic product, VoxNeuro CORE, leverages event-related potentials (ERPs) to provide clinicians with easy-to-interpret reports on their patients’ cognitive function. VoxNeuro’s research and innovation continues to advance the way brain health is managed as the Company works to give everyone’s brain a voice. Visit voxneuro.com to learn more.
VoxNeuro Social Media:
LinkedIn
